SCHEMBL1720626

SCHEMBL1720626

CC(C)N1CCC(c2nn(C)c3[nH]c(=O)c4cc(F)ccc4c23)CC1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 3/20 0.55
TNKS O95271 2/20 0.36
TNKS2 Q9H2K2 2/20 0.36
MAPK14 Q16539 4/20 0.35
MAPK13 O15264 2/20 0.35
MAPK12 P53778 2/20 0.35
MAPK11 Q15759 2/20 0.35
ALK Q9UM73 1/20 0.35
PDE9A O76083 1/20 0.35
DRD2 P14416 4/20 0.34
SLC6A4 P31645 1/20 0.34
VCP P55072 2/20 0.34
JAK2 O60674 1/20 0.34
CCNT1 O60563 1/20 0.34
CDK9 P50750 1/20 0.34
HTR2A P28223 4/20 0.33
HTR7 P34969 4/20 0.33
KCNH2 Q12809 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1719886 0.89 PARP1 (0.59) PARP1TNKSTNKS2MAPK14DRD2
SCHEMBL1720027 0.86 PARP1 (0.72) PARP1JAK2KCNH2
SCHEMBL1720074 0.86 PARP1 (0.76) PARP1DRD2SLC6A4HTR2AHTR7
SCHEMBL1720253 0.85 PARP1 (0.53) PARP1TNKSTNKS2JAK2CDK9
SCHEMBL1720505 0.85 PARP1 (0.65) PARP1DRD2SLC6A4HTR2AHTR7
Hydrochloric Acid SCHEMBL1720668 0.84 PARP1 (0.53) PARP1TNKSTNKS2JAK2CDK9
SCHEMBL1720001 0.74 PARP1 (0.79) PARP1TNKSTNKS2HTR2A
SCHEMBL5522630 0.74 PARP1 (0.54) PARP1TNKSTNKS2
SCHEMBL1720314 0.74 PARP1 (0.46) PARP1TNKSTNKS2
SCHEMBL1719934 0.72 PARP1 (0.41) PARP1TNKSTNKS2JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1566380-B1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2012-01-11 EP claimed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US claimed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP claimed
EP-1566380-B1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2012-01-11 EP disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US disclosed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof PARP1, NQO1, PARP3 PARP1 1/4885TNKS 127/4885TNKS2 282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.